Log in
Enquire now
‌

US Patent 8034943 6-aminoisoquinoline compounds

Patent 8034943 was granted and assigned to Aerie Pharmaceuticals on October, 2011 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Aerie Pharmaceuticals
Aerie Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8034943
Date of Patent
October 11, 2011
Patent Application Number
12701963
Date Filed
February 8, 2010
Patent Citations Received
‌
US Patent 12018012 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
0
‌
US Patent 11707460 Ophthalmic compositions
0
‌
US Patent 11891376 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
0
Patent Primary Examiner
‌
Nizal Chandrakumar
Patent abstract

6-Aminoisoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8034943 6-aminoisoquinoline compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.